IL1A and B-cell non-Hodgkin lymphoma: There is a significant reduction in CRP and in pro-inflammatory cytokines (such as IL-1α, IL-2, IL-8, TNF-α) when intravenous AA s administered after standard treatments by conventional methods in patients with different cancer types (prostate cancer, breast cancer, bladder cancer, pancreatic cancer, lung cancer, thyroid cancer, skin cancer and B-cell lymphoma).